Detalles de la búsqueda
1.
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
Lancet
; 399(10340): 2031-2046, 2022 05 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-35644155
2.
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.
Lancet
; 399(10340): 2015-2030, 2022 05 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-35644154
3.
Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist.
N Engl J Med
; 377(1): 28-40, 2017 07 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28525302
4.
An oral TRPV1 antagonist attenuates laser radiant-heat-evoked potentials and pain ratings from UV(B)-inflamed and normal skin.
Br J Clin Pharmacol
; 75(2): 404-14, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-22775239
5.
Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study.
J Crohns Colitis
; 15(12): 2001-2010, 2021 Dec 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-34077509
6.
Elagolix Pharmacokinetic Profiles in Women With Renal or Hepatic Impairment.
Clin Pharmacol Drug Dev
; 8(8): 1053-1061, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30570832
7.
Elagolix Alone or With Add-Back Therapy in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas: A Randomized Controlled Trial.
Obstet Gynecol
; 132(5): 1252-1264, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30303923
8.
Long-Term Outcomes of Elagolix in Women With Endometriosis: Results From Two Extension Studies.
Obstet Gynecol
; 132(1): 147-160, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29889764
9.
A multitargeted receptor tyrosine kinase inhibitor, SU6668, does not affect the healing of cutaneous full-thickness incisional wounds in SKH-1 mice.
J Invest Surg
; 19(4): 245-54, 2006.
Artículo
en Inglés
| MEDLINE | ID: mdl-16835139
10.
GnRH regulates early growth response protein 1 transcription through multiple promoter elements.
Mol Endocrinol
; 16(2): 221-33, 2002 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-11818496
11.
Population pharmacokinetics and exposure-uric acid analyses after single and multiple doses of ABT-639, a calcium channel blocker, in healthy volunteers.
AAPS J
; 17(2): 416-26, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25567367
12.
A randomized double-blind, placebo-, and active-controlled study of T-type calcium channel blocker ABT-639 in patients with diabetic peripheral neuropathic pain.
Pain
; 156(10): 2013-2020, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26067585
13.
Effects of a T-type calcium channel blocker, ABT-639, on spontaneous activity in C-nociceptors in patients with painful diabetic neuropathy: a randomized controlled trial.
Pain
; 156(11): 2175-2183, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26035253
14.
Erratum to: population pharmacokinetics and exposure-uric acid analyses after single and multiple doses of ABT-639, a calcium channel blocker, in healthy volunteers.
AAPS J
; 17(2): 481-92, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25676842
15.
A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia.
J Pain
; 9(9): 792-805, 2008 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-18524684
16.
Estrogen regulates a tissue-specific calpain in the anterior pituitary.
Biochem Biophys Res Commun
; 295(2): 261-6, 2002 Jul 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-12150941
17.
Comparison of immunohistochemistry for activated caspase-3 and cleaved cytokeratin 18 with the TUNEL method for quantification of apoptosis in histological sections of PC-3 subcutaneous xenografts.
J Pathol
; 199(2): 221-8, 2003 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-12533835
Resultados
1 -
17
de 17
1
Próxima >
>>